ReviewESMO gastrointestinal oncology2023
Individualizing multi-modality therapy for locally advanced rectal cancer: incorporating new data into practice.
Review in ESMO gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ESMO Gastrointestinal Oncology - Expedition into a new era of research and better care.ESMO gastrointestinal oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the publication of several recent studies, the therapeutic approach for locally advanced rectal cancer has been radically transformed and now allows for more tailored, patient-centered care. A patient with a cT3N1 rectal cancer may have numerous treatment options based on the explosion of data, so it is critical to understand how to implement the new approaches in clinical practice. This review summarizes the progress in the management of locally advanced rectal cancer based on the recently published clinical trials and critically appraises the literature on the options for sequencing of therapy and omitting components of multimodality therapy. With the expanding management options, a number of important questions remain regarding how to better individualize use of multimodality therapy for patients with Stage II or III rectal cancer, in particular with regard to predicting response to therapy and identifying the appropriate sequencing and/or omission of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.